{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:40:27Z","timestamp":1760146827638,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health Ricerca Corrente 2019"},{"name":"Banca del Piemonte"},{"name":"Fondazione Venesio"},{"name":"Piaggio research grants"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: Richter syndrome (RS) represents a major unmet need in the lymphoma field, being refractory to chemoimmunotherapy and targeted agents. The BCL-2 inhibitor venetoclax in combination with dose-adjusted EPOCH-R chemoimmunotherapy showed promising efficacy in patients affected by RS. However, responses were not durable, suggesting the need for further treatment optimization. Methods: Here, we report two cases of RS achieving long-term complete remission with intensified chemoimmunotherapy (Rituximab-G-MALL B-ALL\/NHL2002 regimen) plus venetoclax induction, followed by haploidentical hematopoietic stem cell transplant (allo-HSCT). Venetoclax was given continuously for 14 consecutive days after every Rituximab-G-MALL cycle in off-label use. An accelerated venetoclax rump-up schedule was used in both patients to reach the maximal dose. Maximal venetoclax dose was 300 mg and 400 mg in patient 1 and patient 2, respectively. Results: The combined treatment was well tolerated, with no major infective complications or non-hematological toxicities. In both patients, immunosuppression was discontinued within day 180 after transplant with no graft-versus-host-disease flares. Both patients are alive and in continuous complete remission after 60 and 72 months following allo-HSCT. Conclusions: This report supports the feasibility of a combination treatment with BCL-2 inhibitors and intensive chemoimmunotherapy as a bridge to allo-HSCT in RS.<\/jats:p>","DOI":"10.3390\/hematolrep16040075","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T06:53:39Z","timestamp":1734072819000},"page":"795-803","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases"],"prefix":"10.3390","volume":"16","author":[{"given":"Enrico","family":"Derenzini","sequence":"first","affiliation":[{"name":"Oncohematology Division, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"},{"name":"Department of Health Sciences, University of Milan, Via Antonio di Rudin\u00ec 8, 20142 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Cignetti","sequence":"additional","affiliation":[{"name":"Hematology and Cell Therapy, A.O. Mauriziano-Umberto I Hospital, Largo Filippo Turati 62, 10128 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-2248","authenticated-orcid":false,"given":"Valentina","family":"Tabanelli","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Gottardi","sequence":"additional","affiliation":[{"name":"Hematology and Cell Therapy, A.O. Mauriziano-Umberto I Hospital, Largo Filippo Turati 62, 10128 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Gerbino","sequence":"additional","affiliation":[{"name":"Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-4208","authenticated-orcid":false,"given":"Anna","family":"Vanazzi","sequence":"additional","affiliation":[{"name":"Oncohematology Division, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Sammassimo","sequence":"additional","affiliation":[{"name":"Oncohematology Division, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio Maria Edoardo","family":"Maraglino","sequence":"additional","affiliation":[{"name":"Oncohematology Division, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5541-2673","authenticated-orcid":false,"given":"Federica","family":"Melle","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5593-5397","authenticated-orcid":false,"given":"Giovanna","family":"Motta","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7694-8314","authenticated-orcid":false,"given":"Daniela","family":"Malengo","sequence":"additional","affiliation":[{"name":"Pharmacy, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Omodeo Sal\u00e8","sequence":"additional","affiliation":[{"name":"Pharmacy, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Bonello","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences, University of Turin, Via Nizza 52, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Pastano","sequence":"additional","affiliation":[{"name":"Oncohematology Division, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-5128","authenticated-orcid":false,"given":"Stefano","family":"Pileri","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Carnevale Schianca","sequence":"additional","affiliation":[{"name":"Turin Metropolitan Transplant Center, Hematopoietic Stem Cells Unit, Department of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, SP142, Km 3.95, 10060 Candiolo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Tarella","sequence":"additional","affiliation":[{"name":"Oncohematology Division, IEO European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"ref_1","first-page":"285","article-title":"Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia","volume":"4","author":"Richter","year":"1928","journal-title":"Am. J. Pathol."},{"key":"ref_2","first-page":"2375","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/asheducation-2018.1.256","article-title":"Richter transformation in the era of novel agents","volume":"2018","author":"Ding","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100824","DOI":"10.1016\/j.blre.2021.100824","article-title":"Revisiting Richter transformation in the era of novel CLL agents","volume":"49","author":"Petrackova","year":"2021","journal-title":"Blood Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S1470-2045(24)00396-6","article-title":"Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): A multicentre, single-arm, phase 2 trial","volume":"25","author":"Tedeschi","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","article-title":"Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"key":"ref_10","first-page":"1676","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00277-021-04419-w","article-title":"Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: A FILO study of the French compassionate use cohort","volume":"100","author":"Bouclet","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: Report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.leu.2404479","article-title":"Significantly improved PCR based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936","volume":"21","author":"Evans","year":"2007","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood.V87.2.746.bloodjournal872746","article-title":"Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance","volume":"87","author":"Sahota","year":"1996","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","article-title":"European Research Initiative on Chronic Lymphocytic Leukemia (ERIC)\u2014TP53 network. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol. Blood Marrow. Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","article-title":"Why do BCL-2 inhibitors work and where should we use them in the clinic?","volume":"25","author":"Montero","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1182\/bloodadvances.2023012080","article-title":"A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia","volume":"8","author":"Hampel","year":"2024","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.24.00033","article-title":"Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study","volume":"42","author":"Kittai","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hon.3163_28","article-title":"Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with richter\u2019s transformation","volume":"41","author":"Hutchings","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2022-158298","article-title":"Subcutaneous Epcoritamab in Patients with Richter\u2019s Syndrome: Early Results from Phase 1b\/2 Trial (EPCORE CLL-1)","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/4\/75\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:54:00Z","timestamp":1760115240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/4\/75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["hematolrep16040075"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep16040075","relation":{},"ISSN":["2038-8330"],"issn-type":[{"type":"electronic","value":"2038-8330"}],"subject":[],"published":{"date-parts":[[2024,12,13]]}}}